The future of pharmacare
Innovative Medicines Canada supports universal coverage for all Canadians to make prescription drugs more affordable and more accessible to all—regardless of income, age, or postal code.
Any national pharmacare program must ensure Canadians maintain access to at least the same range of cutting-edge medicines they rely on today to survive and maintain their quality of life. No Canadian should have a lower level of coverage than they do today.
Let’s build on the strengths of our current system and help those Canadians who need it most: the uninsured and the underinsured. And we need to make it easier and more affordable for people suffering from rare diseases to get treatment.
Collaboration is essential to the success of national pharmacare in Canada. We look forward to working with federal, provincial and territorial governments and other stakeholders to create a system that works for us all.
- June 12, 2019: IMC responds to final report of Advisory Council on the Implementation of National Pharmacare
- May 8, 2019: Comprehensive Access to Medicines should be the Priority for National Pharmacare in Canada
- March 19, 2019: Budget 2019: Collaboration is essential to success of national pharmacare
- March 6, 2019: Innovative Medicines Canada responds to release of interim report of the Advisory Council for the Implementation of National Pharmacare
- November 29, 2018: National pharmacare: Why a one-size-fits-all approach misses the mark
- September 28, 2018: IMC submission to the Advisory Council for the Implementation of National Pharmacare